Telesis Bio

59 articles about Telesis Bio

• Telesis Bio Reports Fourth Quarter and Full Year 2023 Financial Results

  3/28/2024

  Telesis Bio Inc. (NASDAQ: TBIO), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through advanced, flexible, and rapid automated synthesis in their own lab, today announced financial results for the fourth quarter and year ended December 31, 2023.

• Telesis Bio Announces Select Preliminary Fourth Quarter 2023 Financial Results

  2/26/2024

  Telesis Bio Inc. today announced certain preliminary, unaudited financial results for the fourth quarter and year ended December 31, 2023.

• Telesis Bio Reports Third Quarter 2023 Financial Results

  11/13/2023

  Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, today reported financial results for the third quarter of 2023.

• Telesis Bio to Report Third Quarter Financial Results on Monday, November 13, 2023

  11/7/2023

  Telesis Bio today announced that it will release its third quarter 2023 financial results on Monday, November 13, 2023, after the market closes.

• Telesis Bio Appoints William J. Kullback Chief Financial Officer

  8/29/2023

  Telesis Bio Inc., a leader in automated multi-omic and synthetic biology solutions, has named William J. Kullback as its Chief Financial Officer, effective August 28, 2023.

• Telesis Bio Reports Second Quarter 2023 Financial Results

  8/10/2023

  Telesis Bio Inc., a leader in automated multi-omic and synthetic biology solutions, reported financial results for the second quarter of 2023.

• Telesis Bio to Report Second Quarter Financial Results on Thursday, August 10, 2023

  8/3/2023

  Telesis Bio (Nasdaq: TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced that it will release its second quarter 2023 financial results on Thursday, August 10, 2023, after the market closes.

• Telesis Bio to Present at Jefferies Healthcare Conference 2023

  6/8/2023

  Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, announced that Todd R. Nelson, Ph.D., CEO and Founder of Telesis Bio will present today at the 2023 Jefferies Healthcare Conference, Thursday, June 8, 2023, at 10:00 am Eastern time / 7:00 am Pacific Time.

• Telesis Bio to Present at Antibody Engineering and Therapeutics, Europe 2023

  6/6/2023

  Telesis Bio Inc., a leader in automated multi-omic and synthetic biology solutions, announced they will be showcasing their automated workflow solutions for streamlining discovery workflows in antibody and therapeutics development at Antibody Engineering and Therapeutics, Europe in Amsterdam, The Netherlands.

• Telesis Bio Secures Financing of $28.0 Million

  5/31/2023

  Telesis Bio Inc. announced it has signed a securities purchase agreement with a syndicate of healthcare-focused institutional investors that have agreed to provide initial upfront funding of $28.0 million in gross proceeds to Telesis Bio through a private placement of redeemable convertible preferred stock.

• Telesis Bio to Present at Protein Engineering Summit (PEGS Boston 2023)Showcasing Automated Molecular Biology Workstation for Synthetic Biology and Genomics Applications

  5/15/2023

  Telesis Bio Inc. today announced they will be showcasing their benchtop automation solutions for DNA and mRNA synthesis at Protein Engineering Summit (PEGS Boston 2023) which begins today in Boston, Massachusetts.

• Telesis Bio Reports First Quarter 2023 Financial Results

  5/11/2023

  Telesis Bio Inc., a leader in automated multi-omic and synthetic biology solutions, reported financial results for the first quarter of 2023.

• Telesis Bio to Report First Quarter Financial Results on Thursday, May 11, 2023

  4/27/2023

  Telesis Bio (Nasdaq: TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced that it will release its first quarter 2023 financial results on Thursday, May 11, 2023, after the market closes.

• Telesis Bio Releases BioXp® Select Kits to Enable DNA Amplification and Scale-up

  3/31/2023

  Telesis Bio Inc. announced continued expansion of the BioXp® Select Kit product line, releasing two novel kits to enable DNA amplification and scale-up.

• Telesis Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Guidance

  3/21/2023

  Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, today reported financial results for the fourth quarter and year ended December 31, 2022 and provided financial guidance for 2023.

• Telesis Bio to Present at Festival of Biologics Conference

  3/16/2023

  Telesis Bio Inc. announced Daniel Gibson, Ph.D., CTO and Co-founder of Telesis Bio will present “Building Biology Overnight: Eliminating Synthesis Bottlenecks with Hands-free Automated Synthetic Biology Solutions” at the upcoming Festival of Biologics conference on March 21, 2023.

• Telesis Bio to Report Fourth Quarter and Full Year 2022 Financial Results on Tuesday, March 21, 2023

  3/9/2023

  Telesis Bio  (Nasdaq: TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced that it will release its fourth quarter and full year 2022 financial results on Tuesday, March 21, 2023, after the market closes.

• Telesis Bio to Present at the Cowen 43rd Annual Healthcare Conference

  2/27/2023

  Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced that Todd R. Nelson, PhD, the company’s chief executive officer, will participate in a fireside chat with Steven Mah at the 43rd Annual Cowen Healthcare Conference on Monday, March 6th at 12:50 PM Eastern Time/ 9:50AM Pacific Time.

• Telesis Bio Pre-Announces Preliminary Fourth Quarter 2022 Financial Results

  1/9/2023

  Telesis Bio Inc., a leader in automated multi-omic and synthetic biology solutions, pre-announced certain preliminary, unaudited financial results for the fourth quarter ended December 31, 2022.

• Telesis Bio Inc. Reports Third Quarter 2022 Financial Results

  11/8/2022

  Telesis Bio Inc., a company enabling customers to accelerate the reading and writing of biology, reported financial results and business highlights for the third quarter ended September 30, 2022.